BioMérieux: Stifel reiterates buy rating and TP
(CercleFinance.com) - Stifel confirms its buy recommendation on the stock, leaving its target price unchanged at E125 after its 2024 results.
The analyst notes that BioMérieux reported results 3%/10% ahead of consensus and its sales expectations - mainly thanks to molecular biology - and more particularly the non-respiratory sector and SPOTFIRE, which contributed to the improvement in results.
FY 2025 sales forecasts (>7.0% cFX y-o-y) are in line with expectations, with cEBIT (>10% cFX y-o-y) even slightly above consensus figures, the broker says.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
The analyst notes that BioMérieux reported results 3%/10% ahead of consensus and its sales expectations - mainly thanks to molecular biology - and more particularly the non-respiratory sector and SPOTFIRE, which contributed to the improvement in results.
FY 2025 sales forecasts (>7.0% cFX y-o-y) are in line with expectations, with cEBIT (>10% cFX y-o-y) even slightly above consensus figures, the broker says.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.